Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will present at the 21^st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 pm ET. A webcast of the presentation can be accessed on the company's website under the Investors section and will be available for 30 days post-event.

The company focuses on developing respiratory medicines, with its notable product being YUPELRI^® for COPD treatment. Additionally, it has economic interests related to programs involving Glaxo Group Limited.

DUBLIN, April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 21^st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET (10:30 am PT/6:30 pm IST).

A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.

In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.

Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301518624.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma's presentation at the Needham Virtual Healthcare Conference?

Theravance Biopharma will present on April 13, 2022, at 1:30 pm ET.

How can I access the webcast for Theravance Biopharma's presentation?

The webcast can be accessed on Theravance's website under the Investors section.

What is the focus of Theravance Biopharma?

Theravance Biopharma primarily focuses on discovering, developing, and commercializing respiratory medicines.

What is YUPELRI and what condition does it treat?

YUPELRI^® is a medication for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Does Theravance Biopharma have any collaborations with Glaxo Group Limited?

Yes, Theravance Biopharma has economic interests related to programs with Glaxo Group Limited.